Literature DB >> 32607632

Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid.

Jordi Rimola1, Anna Darnell2,3, Ernest Belmonte2, Victor Sapena4, Carla Caparroz2, Neus Llarch5, Maria Reig5,6, Alejandro Forner3,5,6, Jordi Bruix3,5,6, Carmen Ayuso2,3,6.   

Abstract

OBJECTIVE: To compare the frequency of transient arterial-phase respiratory-motion-related artifacts in liver MRI after extracellular gadolinium and gadoxetic acid injection, and to determine the impact of these artifacts on the detection of focal areas of enhancement on arterial-phase images.
MATERIALS AND METHODS: Intra-patient comparison of 82 cirrhotic patients who prospectively underwent liver MR with extracellular gadolinium and with gadoxetic acid within 1 month. Two readers independently assessed the quality of dynamic T1-weighted MR images (pre-contrast, arterial, and portal-venous phases), rating respiratory-motion-related artifacts on four-point scale (0 [none]-3 [non-diagnostic]). We dichotomized these assessments, which were compared using McNemar's test, defining transient arterial-phase respiratory-motion-related artifacts as a study with a pre-contrast score < 2 and arterial-phase score ≥ 2. Readers also recorded whether at least one focal area of enhancement ≥ 10 mm on arterial phase was present.
RESULTS: The quality of arterial-phase images was worse when obtained after gadoxetic acid than after extracellular gadolinium (p < 0.01), and transient arterial-phase respiratory-motion-related artifacts were more common after gadoxetic acid than after extracellular gadolinium (p < 0.02). At least one area of arterial-phase enhancement ≥ 10 mm was detected more often after extracellular gadolinium than after gadoxetic acid. We observed significant differences on the comparison of the distributions of the presence of arterial-phase artifacts against the presence of arterial-phase enhancement ≥ 10 mm between the two contrast agents (p < 0.0001).
CONCLUSION: In cirrhotic patients, transient arterial-phase respiratory-motion-related artifacts are more common after gadoxetic acid than after extracellular gadolinium. Worse detection of arterial-phase enhancement on gadoxetic acid is only partly due to these artifacts. KEY POINTS: • In a patient-by-patient analysis, the quality of arterial-phase liver MR images was significantly worse with gadoxetic acid than with extracellular gadolinium. • The frequency of transient arterial-phase artifacts was significantly higher after gadoxetic acid injection than after extracellular gadolinium injection. • Differences in the detection of areas of arterial-phase enhancement between MRI studies done with extracellular gadolinium and those done with gadoxetic acid might not be related only to image quality.

Entities:  

Keywords:  Cirrhosis; Gadoxetic acid; Liver; Magnetic resonance

Mesh:

Substances:

Year:  2020        PMID: 32607632     DOI: 10.1007/s00330-020-07039-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  15 in total

1.  Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition.

Authors:  Jason A Pietryga; Lauren M B Burke; Daniele Marin; Tracy A Jaffe; Mustafa R Bashir
Journal:  Radiology       Date:  2014-01-21       Impact factor: 11.105

2.  Reducing Artifacts during Arterial Phase of Gadoxetate Disodium-enhanced MR Imaging: Dilution Method versus Reduced Injection Rate.

Authors:  Young Kon Kim; Wei-Chan Lin; Kyunghyun Sung; Steven S Raman; Daniel Margolis; Yaeji Lim; Seonhye Gu; David Lu
Journal:  Radiology       Date:  2016-12-15       Impact factor: 11.105

Review 3.  Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Lewis R Roberts; Claude B Sirlin; Feras Zaiem; Jehad Almasri; Larry J Prokop; Julie K Heimbach; M Hassan Murad; Khaled Mohammed
Journal:  Hepatology       Date:  2017-11-29       Impact factor: 17.425

4.  Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.

Authors:  Matthew S Davenport; Elaine M Caoili; Ravi K Kaza; Hero K Hussain
Journal:  Radiology       Date:  2014-03-08       Impact factor: 11.105

5.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 7.  Primovist, Eovist: what to expect?

Authors:  Bernard E Van Beers; Catherine M Pastor; Hero K Hussain
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

8.  Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.

Authors:  Simone Gschwend; Wolfgang Ebert; Marcus Schultze-Mosgau; Josy Breuer
Journal:  Invest Radiol       Date:  2011-09       Impact factor: 6.016

9.  Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.

Authors:  Carmen Ayuso; Alejandro Forner; Anna Darnell; Jordi Rimola; Ángeles García-Criado; Luis Bianchi; Ramón Vilana; Rafael Oliveira; Neus Llarch; Jordi Bruix
Journal:  Liver Int       Date:  2019-05-28       Impact factor: 5.828

10.  Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.

Authors:  Jordi Rimola; Alejandro Forner; Víctor Sapena; Neus Llarch; Anna Darnell; Alba Díaz; Angeles García-Criado; Lluís Bianchi; Ramon Vilana; Álvaro Díaz-González; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  Eur Radiol       Date:  2019-08-01       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.